J 2013

Registr selárních tumorů - RESET: diagnostika a léčba akromegalie v České a Slovenské republice v 21. století

HÁNA, Václav, Jan ŠVANCARA, Ľubomíra BANDÚROVÁ, Petr BRABEC, Jan ČÁP et. al.

Basic information

Original name

Registr selárních tumorů - RESET: diagnostika a léčba akromegalie v České a Slovenské republice v 21. století

Name (in English)

Register of Sellar Tumors - RESET: Diagnostics and Therapy of Acromegaly in Czech and Slovak Republics in the 21st Century

Authors

HÁNA, Václav (203 Czech Republic), Jan ŠVANCARA (203 Czech Republic, guarantor, belonging to the institution), Ľubomíra BANDÚROVÁ (203 Czech Republic), Petr BRABEC (203 Czech Republic, belonging to the institution), Jan ČÁP (203 Czech Republic), Viktória ĎUROVCOVÁ (203 Czech Republic), Eva DVOŘÁKOVÁ (203 Czech Republic), Václav Jr. HÁNA (203 Czech Republic), Zuzana JARKOVCOVÁ (203 Czech Republic), Peter KENTOŠ (703 Slovakia), Daniel KLIMEŠ (203 Czech Republic, belonging to the institution), Michal KRČMA (203 Czech Republic), Michal KRŠEK (203 Czech Republic), Ivica LAZÚROVÁ (703 Slovakia), Věra OLŠOVSKÁ (203 Czech Republic), Ján PODOBA (703 Slovakia), Mikuláš PURA (703 Slovakia), Michaela SÁSIKOVÁ (703 Slovakia), Karel STARÝ (203 Czech Republic), Jana STRENKOVÁ (203 Czech Republic, belonging to the institution), Helena ŠIPROVÁ (203 Czech Republic), Juraj ŠTĚŇO (703 Slovakia), Ludmila TREJBALOVÁ (703 Slovakia), Peter VAŇUGA (703 Slovakia), Hedviga WAGNEROVÁ (703 Slovakia), Vladimír WEISS (203 Czech Republic), Dalibor ZEMAN (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution) and Josef MAREK (203 Czech Republic)

Edition

Diabetologie Matabolismus Endokrinologie Výživa, Tigis s.r.o. 2013, 1211-9326

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

30202 Endocrinology and metabolism

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/13:00071826

Organization unit

Faculty of Medicine

Keywords in English

Acromegaly; Leksell gamma-knife; Register; RESET; Surgery; Therapy

Tags

Reviewed
Změněno: 5/2/2014 16:12, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Akromegalie je obvykle diagnostikována až po několikaletém trvání. K potlačení aktivity onemocnění je většinou potřeba kombinace několika léčebných modalit - operace, ozáření, farmakoterapie. Ke zhodnocení diagnostiky a léčby akromegalie v každodenní praxi byl v r. 2008 založen registr RESET, kde jsou uvedeny údaje o léčbě pacientů v osmi terciárních centrech v ČR a SR. Zpětně od roku 2000.

In English

Acromegaly is usually diagnosed after several years of duration. The multimodal therapy - surgery, radiotherpy, pharmacotherapy - is necessary to suppress the activity of the disease in the majority of patients. Register of sellar tumors (RESET) collecting data of patients from eight tertiary centers since the year 2000 was established in 2008 to assess the diagnostics and therapy of acromegaly in a daily practice in the Czech and Slovak Republics. Aim of analysis: diagnostics of acromegaly and effectiveness of its treatment in CR and SR in a period 1. 1. 2000-3. 9. 2013. Patients and results: 343 patients (185 + 158 from CR a SR, resp., 189 women, mean age at diagnosis 49 years). Median time of follow-up was 39.3 months. Three quarters had macroadenoma. 44% of patiens had arterial hypertension (38%) or diabetes mellitus (17%), respectively both (11%). Operated were 81% of patients (reoperated 5%). Normalised IGF-1 three months after surgery was in 54.5% of patients with microadenoma and in 42.4% with macroadenoma. Residual hormonal activity after surgery was treated in the majority of patients with combined radiotherapy and pharmacotherapy. Irradiated were 166 patients and 91% of them underwent radiosurgery with gamma-knife. Patients with operation as part of the complex therapy had faster suppression of hormonal activity. Conclusions: Acromegaly is a serious disease frequently complicated with hypertension and diabetes mellitus. 75% of patients have macroadenoma. The fastest suppression of disease activity is achieved when therapy comprise surgery, alone or in conjunction with other modalities. An individually tailored multimodal therapy is necessary in the majority of patients.